Raymond James & Associates Decreases Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Raymond James & Associates lessened its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 62.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,083 shares of the medical research company's stock after selling 21,649 shares during the period. Raymond James & Associates' holdings in Bio-Rad Laboratories were worth $4,224,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Farther Finance Advisors LLC increased its stake in Bio-Rad Laboratories by 42.3% during the 2nd quarter. Farther Finance Advisors LLC now owns 101 shares of the medical research company's stock worth $38,000 after buying an additional 30 shares in the last quarter. ING Groep NV purchased a new stake in Bio-Rad Laboratories during the 3rd quarter worth approximately $44,000. Pacific Center for Financial Services purchased a new stake in Bio-Rad Laboratories during the 1st quarter worth approximately $49,000. Atlas Capital Advisors LLC purchased a new stake in Bio-Rad Laboratories during the 2nd quarter worth approximately $50,000. Finally, Dark Forest Capital Management LP increased its stake in Bio-Rad Laboratories by 1,160.0% during the 1st quarter. Dark Forest Capital Management LP now owns 126 shares of the medical research company's stock worth $60,000 after buying an additional 116 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Insiders Place Their Bets

In other news, EVP Michael Crowley sold 3,000 shares of the company's stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the sale, the executive vice president now owns 6,942 shares of the company's stock, valued at $2,332,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 17.06% of the stock is owned by insiders.

Bio-Rad Laboratories Trading Down 3.7 %

NYSE:BIO traded down $11.42 during trading hours on Friday, reaching $300.45. 250,762 shares of the stock were exchanged, compared to its average volume of 199,495. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14. The business has a 50-day moving average of $333.37 and a two-hundred day moving average of $322.48. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $494.05. The company has a market capitalization of $8.57 billion, a price-to-earnings ratio of -13.98 and a beta of 0.87.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.10 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The company had revenue of $681.18 million for the quarter, compared to analysts' expectations of $685.00 million. During the same period in the prior year, the firm earned $3.31 earnings per share. The firm's revenue was down 6.7% compared to the same quarter last year. On average, equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BIO shares. Royal Bank of Canada lowered their target price on Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating on the stock in a report on Friday, February 16th. UBS Group boosted their target price on Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a "buy" rating in a report on Friday, February 16th. StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Friday, April 5th. Finally, Citigroup cut Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $400.00 to $365.00 in a report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $468.00.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.